|
Changes in CRP and ESR with treatment |
||||
| Time |
Change in CRP (n = 37) |
Change in ESR (n = 20) |
||
|
|
||||
| oMTX |
rMTX |
oMTX |
rMTX |
|
|
|
||||
| 3 months |
-1.5 (-28.0 and +24.2) |
-7.0 (-49.0 and +52.2) |
-7.0 (-32.7 and +24.5) |
-25.6 (-33.0 and +23.1) |
| 6 months |
-13.9 (-59.6 and +16.2) |
-11.5 (-49.4 and +22.2) |
-20.6 (-50.9 and +19.9) |
-12.1 (-38.2 and +52.5) |
| 9 months |
-20.9 (-60.1 and +19.0) |
-14.8 (-50.4 and +38.4) |
-15.3 (-50.6 and +22.2) |
-24.2 (-55.3 and +37.6) |
| 12 months |
-23.6 (-51.6 and +6.8) |
-26.8 (-68.8 and +0.0) |
-20.2 (-51.0 and +41.1) |
-36.1 (-61.5 and +16.1) |
| AUC |
-14.0 (-41.2 and +16.8)* |
-10.3 (-53.0 and +37.9)* |
-6.1 (-27.6 and +20.4)** |
-17.7 (-45.9 and +25.1)** |
|
Shown are the relative improvements in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at 3, 6, 9, and 12 months after treatment initiation. Values are expressed as median (1st and 3rd quartile) of % change. *P = 0.80, by Wilcoxon test; **P = 0.43, by Wilcoxon test. oMTX, original methotrexate course; rMTX, re-employed methotrexate course. | ||||
Kapral et al. Arthritis Research & Therapy 2006 8:R46 doi:10.1186/ar1902 |
||||